تحميل...

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in E...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Nat Commun
المؤلفون الرئيسيون:	Spoerke, Jill M., Gendreau, Steven, Walter, Kimberly, Qiu, Jiaheng, Wilson, Timothy R., Savage, Heidi, Aimi, Junko, Derynck, Mika K., Chen, Meng, Chan, Iris T., Amler, Lukas C., Hampton, Garret M., Johnston, Stephen, Krop, Ian, Schmid, Peter, Lackner, Mark R.
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Publishing Group 2016
الموضوعات:	Article
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4869259/ https://ncbi.nlm.nih.gov/pubmed/27174596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms11579
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

مواد مشابهة